[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oculis Holding Ag (OCS)

Oculis Holding Ag (OCS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 731,178
  • Shares Outstanding, K 57,984
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -119,440 K
  • EBIT $ -104 M
  • EBITDA $ -103 M
  • 60-Month Beta 0.44
  • Price/Sales 525.74
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 153.37% (+1.93%)
  • Historical Volatility 58.19%
  • IV Percentile 57%
  • IV Rank 58.14%
  • IV High 205.40% on 05/26/26
  • IV Low 81.11% on 04/15/26
  • Expected Move (DTE 34) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 90
  • Volume Avg (30-Day) 198
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 5,543
  • Open Int (30-Day) 5,276
  • Expected Range 12.19 to 12.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 4
  • High Estimate $-0.45
  • Low Estimate $-0.51
  • Prior Year $-0.59
  • Growth Rate Est. (year over year) +18.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.88 +12.04%
on 06/18/26
14.35 -15.05%
on 07/06/26
+0.89 (+7.88%)
since 06/17/26
3-Month
10.52 +15.87%
on 06/08/26
34.47 -64.64%
on 05/11/26
-15.27 (-55.61%)
since 04/17/26
52-Week
10.52 +15.87%
on 06/08/26
34.47 -64.64%
on 05/11/26
-5.98 (-32.91%)
since 07/17/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to...

OCS : 12.19 (-3.33%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to...

OCS : 12.19 (-3.33%)
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding...

OCS : 12.19 (-3.33%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS).  Such investors are advised...

OCS : 12.19 (-3.33%)
Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky

Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema.

OCS : 12.19 (-3.33%)
Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation

New York, New York--(Newsfile Corp. - June 8, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential...

OCS : 12.19 (-3.33%)
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ:...

OCS : 12.19 (-3.33%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to...

OCS : 12.19 (-3.33%)
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

Oculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.

OCS : 12.19 (-3.33%)
OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations

Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints....

OCS : 12.19 (-3.33%)

Business Summary

Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland.

See More

Key Turning Points

3rd Resistance Point 13.25
2nd Resistance Point 13.00
1st Resistance Point 12.60
Last Price 12.19
1st Support Level 11.95
2nd Support Level 11.70
3rd Support Level 11.30

See More

52-Week High 34.47
Fibonacci 61.8% 25.32
Fibonacci 50% 22.50
Fibonacci 38.2% 19.67
Last Price 12.19
52-Week Low 10.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.